Compositions, methods, and kits for eliciting an immune response
The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.
1. A method for eliciting in a subject an immune response to a cancer cell that expresses a CMV antigen, the method comprising:
selecting a subject in need of treatment related to the presence of the cancer cell; and
administering to the subject a composition comprising an effective amount of a T-lymphocyte or an antigen presenting cell sensitized with at least one CMV antigen, wherein the effective amount of the T-lymphocyte or the antigen presenting cell is sufficient to elicit the immune response to the cancer cell that expresses the CMV antigen.
2. The method of claim 1 , wherein the at least one CMV antigen is a polypeptide, or an immunogenic fragment thereof, selected from the group consisting of: a capsid polypeptide, a tegument polypeptide, and a envelope polypeptide.
3. The method of claim 1 , wherein the at least one CMV antigen is a polypeptide, or an immunogenic fragment thereof, selected from the group consisting of: phosphoprotein unique long 83 (ppUL83; a/k/a pp65), glycoprotein UL55 (gpUL55; a/k/a gB), UL123 immediate early 1 (IE1) protein, UL122 IE2 protein, UL111A (a/k/a mtrII), US28, ppUL32, ppUL65, ppUL80a, ppUL82, ppUL98a, ppUL99, gpUL4 (a/k/a gp48), gpUL16, gpUL18 (a/k/a MHC), gpUL75 (a/k/a gH), gpUL100, gpUL110 (a/k/a gM), gpUL115 (a/k/a gL), pUL46, pUL48, pUL56, pUL86 (a/k/a MCP), glycoprotein unique short 10 (gpUS10), gpUS11, glycoprotein complex II (gcII), gp65, and gp93.
4. The method of claim 1 , wherein the at least one CMV antigen comprises an amino acid sequence as set forth in SEQ ID NO:109.
5. The method of claim 1 , wherein the composition further comprises at least one adjuvant.
6. The method of claim 5 , wherein the adjuvant is incomplete Freund's adjuvant (Montanide ISA 51) or Corynebacterium granulosum P40.
7. The method of claim 1 , wherein the composition further comprises a cytokine.
8. The method of claim 7 , wherein the cytokine is selected from the group consisting of: GM-CSF, G-CSF, IL-2, IL-4, IL-7, IL-12, IL-15, IL-21, TNF-α, and M-CSF.
9. The method of claim 1 further comprising of detecting the expression of the CMV antigen by the cancer cell in the subject.
10. A method for eliciting in a subject an immune response to a cancer cell that expresses a CMV antigen, the method comprising:
selecting a subject in need of treatment related to the presence of the cancer cell, wherein the cancer cell is a glioblastoma multiforme (GBM) cancer cell; and
administering to the subject a composition comprising an effective amount of an antigen presenting cell sensitized with at least one CMV antigen, wherein the effective amount of the antigen presenting cell is sufficient to elicit the immune response to the cancer cell that expresses the CMV antigen, wherein the antigen presenting cell is a dendritic cell.